Company Spotlight: JLABS @ Shanghai
Johnson & Johnson’s network of healthcare innovation incubators, JLABS, opened its doors in Shanghai in June 2019 and now stands as the largest such institution of 13 globally. JLABS @…
Address: 32 Kexue Yuan Road, Zhonggancun Life Science Park, Changping District, Beijing 102206,China
Tel: +86 10 8072 8800
Web: http://www.bridgelaboratories.com/
Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is US owned and headquartered in Gaithersburg, Maryland, with lab facilities in both the US and Beijing, China. Bridge is known for its extensive work in toxicology, including vaccines, developmental and reproductive toxicology (DART), and safety pharmacology. The company’s AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide.
Drug development services
Johnson & Johnson’s network of healthcare innovation incubators, JLABS, opened its doors in Shanghai in June 2019 and now stands as the largest such institution of 13 globally. JLABS @…
Pierre A Morgon, SVP International Business for CanSino Biotechnology (CanSinoBIO) – a Chinese vaccine biotech developing one of the frontrunner COVID-19 vaccine candidates – shares how his extensive international career…
Highly potent neutralizing antibodies may be the key to laying a foundation for COVID-19 treatment, according to a Chinese research team led by Peking University. The worldwide race against…
A roundup of some of the top stories in China’s healthcare and life sciences industry, including challenges for Chinese biotechs in the post-pandemic era, why the country needs a biosecurity…
Dr Joan Shen, CEO of I-Mab Biopharma, shares her impressive career journey across companies like Pfizer, Janssen and Jiangsu Hengrui, before joining I-Mab, as well as introducing what I-Mab 2.0…
A roundup of the latest news in Chinese pharma, including a US IPO for Burning Rock Biotech, positive news on CanSino’s COVID-19 vaccine trials, and WuXi Biologics’s first US facility.…
Dr Sharon Chan, head of JLABS @ Shanghai – the first JLABS presence in Asia-Pacific as well as the largest globally – shares how Johnson & Johnson is investing in…
Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly adapting their portfolio strategies to launch products on the large but…
Established in December 2012, in less than a decade, Chinese biotech Junshi Biosciences has already transformed itself into a publicly-listed commercial company with a successful USD 450 million IPO on…
PharmaBoardroom caught up with Alphamab Oncology’s founder, chairman and CEO Dr Xu Ting again 16 months after our last interview to hear about their successful HKEX IPO in December 2019,…
Top recent news from Chinese pharma, including listings on the Hong Kong Stock Exchange, Junshi’s out-licensing of a potential COVID-19 treatment to Lilly, and Ascentage being granted US FDA orphan…
A selection of recent big stories from Chinese pharma, including Novo Nordisk’s updated China strategy, Chinese biotechs’ funding successes, and some significant regulatory approvals. In Q1 2020, China’s regulator…
See our Cookie Privacy Policy Here
